Leerink Partners Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $27

Benzinga · 1d ago
Leerink Partners analyst Andrew Berens maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $39 to $27.